GlassScriptPhysician profile
Carolyn E Williams
NPI 1558876300
$8,161.52
in general payments reported to CMS, 2019-2025
27 companies · $3,380 in 2025
The $3,380 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $521 · 2022: $1,037 · 2023: $2,358 · 2024: $865 · 2025: $3,380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,828 · Travel and Lodging: $2,775 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,828.27 |
| Travel and Lodging | $2,774.53 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $2,966.13 | 2021-2025 | Sapien 3 Ultra Resilia, Pascal |
| Boston Scientific Corporation | $2,641.12 | 2021-2025 | Watchman Access System, Watchman Flx, General - Structural Heart |
| Abbott Laboratories | $892.34 | 2021-2024 | Mitraclip, Optis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $560.19 | 2021-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $125.16 | 2021-2025 | Farxiga, Wainua |
| Pfizer INC. | $106.97 | 2022-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $106.56 | 2024 | Arcalyst |
| Atricure, INC. | $99.14 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $77.62 | 2024-2025 | Uptravi, Opsumit |
| Kiniksa Pharmaceuticals, LTD. | $74.13 | 2023 | Arcalyst |
| Scpharmaceuticals INC. | $66.14 | 2024-2025 | |
| Medtronic, INC. | $62.59 | 2025 | Corevalve Evolut R |
| Abiomed | $55.91 | 2023 | Impella |
| Novo Nordisk INC | $45.08 | 2023 | Rybelsus, Ozempic |
| Inspire Medical Systems, INC. | $35.23 | 2025 | Inspire |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $34.09 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $29.11 | 2023-2024 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $28.64 | 2023 | Evkeeza |
| Genentech USA, INC. | $21.35 | 2025 | Itovebi |
| Sanofi-Aventis U.S. LLC | $20.75 | 2024 | |
| Vital Connect, INC | $20.00 | 2024 | Vitalpatch Rtm |
| Amarin Pharma, INC. | $19.84 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $19.56 | 2025 | Eliquis |
| Genzyme Corporation | $16.69 | 2025 | |
| Irhythm Technologies, INC. | $12.90 | 2022 | |
| Altathera Pharmaceuticals LLC | $12.51 | 2025 | Sotalol Hydrochloride |
| Amgen INC. | $11.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carolyn Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.